Universal reference book for medicines
Name of the drug: FUZIDERM (FUSIDERM)

Active substance: fusidic acid

Type: Antibiotic for external use

Manufacturer: BIOSINTEZ (Russia) manufactured by LEO Laboratories (Ireland)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

Has a bacteriostatic or bactericidal effect. The mechanism of action is associated with the suppression of protein synthesis by inhibiting the factor necessary for the translocation of protein subunits and elongation of the peptide chain, which subsequently leads to the death of the pathogen.
Highly active against Staphylococcus spp., Especially Staphylococcus aureus and Staphylococcus epidermidis (including methicillin-resistant strains), Nocardia asteroides, Clostridium spp.

Less active against Streptococcus spp., Enterococcus spp., Neisseria spp., Bacteroides spp., Mycobacterium tuberculosis, Mycobacterium leprae.

Fusidic acid is active against some protozoa, including Giardia lamblia, Plasmodium falciparum.

After oral and intravenous administration is widely distributed in the body.
Fusidic acid accumulates in pus, sputum, bone, synovial fluid, sequestrants, burn scabs, brain abscesses in concentrations exceeding the MIC for Staphylococcus aureus (0.03-0.16 μg / ml). Metabolised in the liver. It is excreted with bile, a small amount - with urine.
With external application, fusidic acid penetrates well both through damaged and healthy skin, while systemic absorption is low.

When applied topically, it penetrates well into the intraocular fluid.
Therapeutic concentrations persist in the lacrimal and intraocular fluid for at least 12 hours.
Infectious and inflammatory diseases caused mainly by Staphylococcus spp .: for oral and / or intravenous administration - cerebral abscess, bone and joint infections, endocarditis, eye, septicemia, pneumonia, skin and soft tissue infections, infectious and inflammatory complications in cystic fibrosis, wound infection;
for external use - impetigo, carbuncles, boils, infected wounds, hydradenitis, folliculitis, paronychia, sycosis of the beard, erythrasma, common acne; for topical application in ophthalmology - conjunctivitis, blepharitis, barley, dacryocystitis, keratitis, infections associated with the removal of a foreign body from the conjunctiva and the cornea.
Adults inside - 500 mg every 8 hours. Children under the age of 1 g - 50 mg / kg / day in 3 divided doses, at the age of 1-5 years - 250 mg 3 times / day, at the age of 5-12 years - by 500 mg 3 times / day, over 12 years - 750 mg 3 times / day.

Adults and children older than 12 years inside - 250-500 mg 2-3 times / day.
Adults IV in the form of infusions - 500 mg 3 times / day. Duration of infusion - at least 2 hours.
Children under the age of 12 years inside - 50 mg / kg / day in 3 divided doses;
in / in - 20 mg / kg / day, the frequency of administration - 3 times / day.
The maximum daily intake for adults with iv introduction is 2 g.

With external application fusidic acid is applied a thin layer on the affected skin 2-3 times / day for 7 days.
In the treatment of acne vulgaris, longer courses of therapy are required.
Locally with eye diseases apply 2 times / day.
Treatment should continue for 2 days after the disappearance of the clinical symptoms of the disease.
On the part of the digestive system: dyspeptic symptoms, jaundice, and liver dysfunction are possible.

Allergic reactions: a skin rash is possible.

Hypersensitivity to fusidic acid.

If it is necessary to use during pregnancy and lactation, it is necessary to evaluate the prospective benefit to the mother and the potential risk to the fetus.

In experimental studies , it has been established that fusidic acid does not have a teratogenic effect.

Fusidic acid penetrates the placental barrier.
In vitro experiments, it has been established that fusidic acid replaces bilirubin in association with albumin. Therefore, the use of fusidic acid in the third trimester of pregnancy should be avoided because of the possible development of nuclear jaundice in newborns. This fact should be considered when it is necessary to use children with jaundice and acidosis in newborns (including prematurity).
Fusidic acid is excreted in breast milk in very low concentrations.

It should be noted that fusidic acid can be used for violations of kidney function and in cases where the use of other antibiotics is contraindicated.

The application is possible according to the dosing regimen.

It should be noted that fusidic acid can be used for violations of kidney function and in cases where the use of other antibiotics is contraindicated.

There was no cross-sensitivity to other antibiotics.

In severe infections, as well as in cases where long-term treatment is necessary, fusidic acid should be combined with other antibiotic-active antibodies to staphylococci, in order to reduce the risk of developing resistance.

With simultaneous application with colestyramine, insoluble complexes are formed, which leads to a decrease in the concentration of fusidic acid in the blood plasma.

With the simultaneous use of fusidic acid with penicillins, penicillinase resistant, cephalosporins, erythromycin, rifampicin, lincomycin, additive action or synergism is observed.

Pharmaceutical interaction

Solutions for infusions containing fusidic acid are incompatible with kanamycin, gentamicin, vancomycin, cephaloridine, carbenecillin, amino acid solutions, blood substituting and calcium-containing drugs.
The precipitation of fusidic acid can occur in infusion solutions at pH below 7.4.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!